All stock lists
Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
Healthcare · Biotechnology
225.94+1.91 (+0.85%)
Insider Score
––Not scored
ALNY Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
ALNY Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 |
| Revenue | 1.29 B | 1.17 B | 1.10 B | 1.25 B | 773.69 M |
| Revenue Growth (YoY) | 66.86 % | — | — | — | — |
| Cost of Revenue | 298.45 M | 211.12 M | 267.72 M | 200.15 M | 142.95 M |
| Gross Profit | 992.50 M | 956.05 M | 829.31 M | 1.05 B | 630.74 M |
| SG&A Expense | 347.92 M | 322.55 M | 325.37 M | 322.08 M | 323.31 M |
| R&D Expense | 413.13 M | 364.87 M | 372.22 M | 358.81 M | 323.62 M |
| Operating Expenses | 761.06 M | 687.42 M | 697.59 M | 680.89 M | 646.93 M |
| Operating Income | 231.44 M | 268.64 M | 131.72 M | 367.98 M | -16.20 M |
| Pretax Income | 177.81 M | 221.65 M | 161.14 M | 238.97 M | -41.31 M |
| Tax Provision | 13.31 M | 15.66 M | -25.28 M | -12.12 M | 30.92 M |
| Net Income | 164.49 M | 205.99 M | 186.42 M | 251.08 M | -72.23 M |
| EPS (Basic) | 1.23 | 1.55 | 0.84 | 1.91 | -0.55 |
| EPS (Diluted) | 1.21 | 1.51 | 0.82 | 1.84 | -0.55 |
| Shares Outstanding | 133.61 M | 132.89 M | 132.23 M | 131.45 M | 130.63 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.